TMEM158 Inhibitors
Chemical inhibitors of TMEM158 operate through different mechanisms to impede the functional activity of this protein. PD 98059 and U0126 are selective inhibitors that target MEK1 and MEK2 enzymes, which are crucial in the MAPK/ERK signaling pathway. By inhibiting these kinases, they prevent the phosphorylation and activation of ERK, which is a downstream effector in the pathway TMEM158 is associated with. Consequently, the functional activities of TMEM158 that rely on this signaling cascade are inhibited. Similarly, LY294002 and Wortmannin are inhibitors that target the PI3K enzyme, a pivotal component of the PI3K/AKT signaling pathway. By impeding the kinase activity of PI3K, these inhibitors prevent the downstream signaling that would typically result in TMEM158 activation. The inhibition of PI3K consequently leads to a decrease in the functional activity of TMEM158, as the protein is involved in cellular processes downstream of PI3K.
Furthermore, Rapamycin directly inhibits mTOR, a key protein in the PI3K/AKT/mTOR pathway, which affects TMEM158's function. The inhibition of mTOR by Rapamycin results in a reduction of TMEM158's functional activity due to the disruption of downstream signaling events. SB203580 and SP600125 target different kinases within the MAPK family; SB203580 inhibits p38 MAPK, while SP600125 inhibits JNK. These kinases are involved in stress-activated signaling pathways and their inhibition leads to reduced TMEM158 activity related to stress responses. PP2, an inhibitor of the Src family kinases, impedes multiple signaling cascades that activate TMEM158. Erlotinib and Lapatinib, which inhibit EGFR and HER2/neu tyrosine kinases, respectively, also lead to the downregulation of TMEM158 function by blocking the activation of these receptors and their subsequent signaling pathways. Lastly, multi-kinase inhibitors like Sorafenib and Sunitinib, which target several enzymes including those in the RAF/MEK/ERK pathway and receptor tyrosine kinases like PDGFR and VEGFR, respectively, lead to broad inhibition of the signaling networks that TMEM158 is involved in, resulting in a comprehensive decrease in its functional activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a selective inhibitor of MEK, which blocks MAPK/ERK pathway activation. TMEM158 is reported to be associated with the RAS/RAF/MEK/ERK signaling pathway. Inhibition of MEK by PD 98059 can inhibit the downstream effects of this pathway, thereby functionally inhibiting TMEM158. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 acts similarly to PD 98059 by inhibiting MEK1 and MEK2, which are upstream of the ERK pathway. TMEM158's function is reliant on this pathway for certain cellular responses, and inhibiting this pathway with U0126 can result in the functional inhibition of TMEM158. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, a component of the PI3K/AKT signaling pathway. Given that TMEM158 is involved in pathways downstream of PI3K, LY294002 can inhibit signaling events that would otherwise activate TMEM158, leading to its functional inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor. By preventing PI3K from phosphorylating and activating AKT, it indirectly hampers the cellular processes that TMEM158 is involved in, effectively inhibiting TMEM158's function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a key regulator in the PI3K/AKT/mTOR pathway, which is linked with TMEM158 function. By inhibiting mTOR activity, Rapamycin can inhibit the downstream effects that contribute to the functional activity of TMEM158. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, a protein kinase involved in the stress-activated MAPK pathway. TMEM158 is implicated in stress responses, and inhibition of this pathway by SB203580 can lead to functional inhibition of TMEM158. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK signaling pathways. By blocking JNK, SP600125 can disrupt the signaling processes in which TMEM158 is involved, thus inhibiting its function. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family kinases. Since Src kinases can activate several pathways including those involving TMEM158, inhibition by PP2 can lead to a decrease in TMEM158's functional activity. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an EGFR tyrosine kinase inhibitor. By blocking EGFR activation, it inhibits downstream signaling pathways that include the functional activities of TMEM158, leading to its inhibition. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor that targets both EGFR and HER2/neu. Inhibition of these receptors can diminish the signaling pathway activities involving TMEM158, resulting in its functional inhibition. | ||||||